JPWO2022020108A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022020108A5 JPWO2022020108A5 JP2023504636A JP2023504636A JPWO2022020108A5 JP WO2022020108 A5 JPWO2022020108 A5 JP WO2022020108A5 JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023504636 A JP2023504636 A JP 2023504636A JP WO2022020108 A5 JPWO2022020108 A5 JP WO2022020108A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- disease
- antibody
- myopathy
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055785P | 2020-07-23 | 2020-07-23 | |
| US63/055,785 | 2020-07-23 | ||
| US202063061842P | 2020-08-06 | 2020-08-06 | |
| US63/061,842 | 2020-08-06 | ||
| US202063069078P | 2020-08-23 | 2020-08-23 | |
| US63/069,078 | 2020-08-23 | ||
| US202163143831P | 2021-01-30 | 2021-01-30 | |
| US63/143,831 | 2021-01-30 | ||
| US202163181450P | 2021-04-29 | 2021-04-29 | |
| US63/181,450 | 2021-04-29 | ||
| PCT/US2021/041003 WO2022020108A1 (en) | 2020-07-23 | 2021-07-09 | Muscle-targeting complexes and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023535074A JP2023535074A (ja) | 2023-08-15 |
| JPWO2022020108A5 true JPWO2022020108A5 (https=) | 2024-07-18 |
| JP2023535074A5 JP2023535074A5 (https=) | 2024-07-18 |
| JP7828947B2 JP7828947B2 (ja) | 2026-03-12 |
Family
ID=79728348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504636A Active JP7828947B2 (ja) | 2020-07-23 | 2021-07-09 | 筋標的化複合体およびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230287108A1 (https=) |
| EP (1) | EP4185329A4 (https=) |
| JP (1) | JP7828947B2 (https=) |
| CN (2) | CN116194470B (https=) |
| AU (1) | AU2021313058A1 (https=) |
| CA (1) | CA3186755A1 (https=) |
| WO (1) | WO2022020108A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283531A2 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
| CA3174286A1 (en) | 2020-04-02 | 2021-10-07 | Robert PLACE | Targeted inhibition using engineered oligonucleotides |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023168427A1 (en) * | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
| WO2025215092A1 (en) * | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
| PE20141114A1 (es) * | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| TWI769982B (zh) * | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| RU2753493C2 (ru) | 2016-12-15 | 2021-08-17 | Эббви Байотерапьютикс Инк. | Анти-ох40 антитела и их применение |
| RU2771292C2 (ru) | 2017-10-14 | 2022-04-29 | Эббви Инк. | Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения |
| AR126019A1 (es) * | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| JP7576542B2 (ja) * | 2018-08-02 | 2024-10-31 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびそれらの使用 |
| WO2020028842A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| CN116348138A (zh) * | 2020-07-23 | 2023-06-27 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| AU2021318851A1 (en) * | 2020-07-23 | 2023-03-16 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20230046297A (ko) * | 2020-07-23 | 2023-04-05 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US20230346966A1 (en) * | 2020-07-23 | 2023-11-02 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
-
2021
- 2021-07-09 WO PCT/US2021/041003 patent/WO2022020108A1/en not_active Ceased
- 2021-07-09 CA CA3186755A patent/CA3186755A1/en active Pending
- 2021-07-09 US US18/017,180 patent/US20230287108A1/en active Pending
- 2021-07-09 CN CN202180064691.XA patent/CN116194470B/zh active Active
- 2021-07-09 JP JP2023504636A patent/JP7828947B2/ja active Active
- 2021-07-09 CN CN202511290690.3A patent/CN121270701A/zh active Pending
- 2021-07-09 EP EP21845571.5A patent/EP4185329A4/en active Pending
- 2021-07-09 AU AU2021313058A patent/AU2021313058A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022020108A5 (https=) | ||
| CN116194470B (zh) | 肌肉靶向复合物及其用途 | |
| JP2021533198A5 (https=) | ||
| JP2021533200A5 (https=) | ||
| JP7804685B2 (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 | |
| JPWO2020028864A5 (https=) | ||
| JPWO2020028857A5 (https=) | ||
| JPWO2021142313A5 (https=) | ||
| JP2021532832A5 (https=) | ||
| CN116368150A (zh) | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 | |
| CN112912399A (zh) | 肌肉靶向复合物及其用于治疗蓬佩病的用途 | |
| JP2021533199A5 (https=) | ||
| CN116348138A (zh) | 抗转铁蛋白受体（tfr）抗体及其用途 | |
| JP2021533197A5 (https=) | ||
| CN112930197A (zh) | 肌肉靶向复合物及其用途 | |
| CN112955153A (zh) | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 | |
| CN116438304A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 | |
| CN112955154A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 | |
| CN116348139A (zh) | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 | |
| CN118251238A (zh) | 肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途 | |
| CN118401553A (zh) | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 | |
| CN114025805A (zh) | 制备蛋白质-寡核苷酸复合物的方法 | |
| CN113166240A (zh) | 肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途 | |
| JP2025512469A (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 | |
| KR20250004771A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여 |